Premium
The tolerance of anisometropia
Author(s) -
Krarup Therese Grønhøj,
Nisted Ivan,
Christensen Ulrik,
Kiilgaard Jens Folke,
la Cour Morten
Publication year - 2020
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/aos.14310
Subject(s) - anisometropia , medicine , ophthalmology , visual acuity , stereoscopic acuity , optometry , refractive error
Purpose This study examines aniseikonia, Aniseikonia tolerance range ( ATR ), anisometropia and patient‐reported outcomes ( PRO ) in an anisometropic population compared with a non‐anisometropic population. The relationship between anisometropia and aniseikonia is determined, and the correlations between aniseikonia, anisometropia and ATR versus PRO are described. Methods One hundred and twenty‐three patients with IOL ‐induced anisometropia ≥1 dioptre (D) (the anisometropic group) and 17 patients who had IOL ‐induced anisometropia <1 D (the control group) were included. Best corrected visual acuity, aniseikonia, ATR and stereoacuity were examined, and two questionnaires were completed: convergence insufficiency symptom survey ( CISS ) and Visual Function Questionnaire ( VFQ ‐39). Results One hundred and thirteen patients had anisometropia >1 and <3 D, and 10 patients had anisometropia >3 D. There was no difference in PRO between the control group and the anisometropic group (Mann–Whitney, p‐values VFQ : 0.96, CISS : 0.06). There was no correlation between anisometropia and PRO (Spearman's rank correlation test p‐values: VFQ : 0.54, CISS : 0.57). Patients with low ATR were more sensitive towards anisometropia and had lower PRO than patients with high ATR (Mann–Whitney, p‐values: VFQ : 0.0008, CISS : 0.11). A large tolerance of aniseikonia was observed. Conclusion No correlation between PRO and anisometropia or aniseikonia was found. Patients with low ATR are at risk of visual complaints if they are exposed to IOL ‐induced anisometropia. ATR might be a future screening tool in cataract patients.